Kane Biotech Expands Distribution for revyve™ Gel in Qatar
Kane Biotech Inc. (TSX-V: KNE; OTCQB: KNBIF) has announced a significant step forward by signing a three-year distribution agreement with Qatar Datamation Systems (QDS) for its revyve™ Antimicrobial Wound Gel. This partnership aims to effectively enter the Qatar wound care market.
Strategic Partnership with QDS
Marc Edwards, the President & CEO of Kane Biotech, shared his enthusiasm about this new collaboration, stating, "Kane continues its global commercialization of revyve™ with its second distribution agreement in the Middle East. We’re looking forward to partnering with QDS to bring revyve™ to market in Qatar, and we are confident that the product will be well-received in the region.” This agreement underscores Kane Biotech's commitment to expanding its international footprint.
Overview of revyve™ Antimicrobial Wound Gel
The revyve™ Antimicrobial Wound Gel is part of Kane Biotech’s comprehensive range of solutions designed to meet critical needs in wound care. As healthcare challenges grow, particularly with infections caused by microbial biofilms, products like revyve™ become increasingly vital. Kane Biotech is dedicated to creating innovative solutions that not only prevent infections but also enhance the speed of wound healing.
Previous Distribution Agreements
This new agreement positions Kane Biotech as a rising player in the Middle Eastern healthcare market, complementing its existing partnerships. The company has previously secured distribution agreements with Razan Medical & Surgical Equipment Trading LLC in the UAE, ProgenaCare Global LLC in the United States, and Salud Pharma S.A. across several Latin American countries, including Colombia, Costa Rica, and Panama. These collaborations highlight the global appeal and versatility of the revyve™ product line.
Certification and Market Expansion
Alongside its international agreements, Kane Biotech has successfully achieved the ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification. This certification emphasizes the company's commitment to quality assurance and positions it favorably for future expansion into additional markets, including Canada.
Innovation in Healthcare
Kane Biotech prides itself on leading the way in biotechnological innovation, focusing on the research, development, and commercialization of products that combat harmful microbial biofilms. The company has built a strong portfolio of biotechnologies and intellectual property, which includes 68 patents and patents pending, trade secrets, and trademarks. Their advanced products, such as DispersinB, Aledex, coactiv+, DermaKB, DermaKB Biofilm, and revyve™, are designed to meet the evolving needs of modern healthcare.
About Kane Biotech
Kane Biotech is a biotechnology company committed to advancing technologies and solutions within the healthcare industry. The firm engages in thorough research to develop products that can prevent and eliminate microbial biofilms, which pose significant risks in clinical environments. Their dedication to innovation is reflected in their extensive research partnerships and a robust pipeline of patented products.
About QDS
Qatar Datamation Systems has been a key player in the Qatari healthcare sector for 23 years, significantly enhancing the quality of medical technology available in the region. With a focus on building strong relationships with leading manufacturers, QDS is dedicated to introducing innovative healthcare solutions, ensuring high patient satisfaction and quality service across Qatar's medical institutions.
Contact Information
Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
Email: medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
Email: rdupuis@kanebiotech.com
Frequently Asked Questions
1. What is the main product announced by Kane Biotech?
The main product is revyve™ Antimicrobial Wound Gel, specifically targeting the Qatar market.
2. What is the significance of the agreement with QDS?
The agreement with QDS is crucial as it establishes Kane Biotech's foothold in the Middle East, expanding its market reach for revyve™.
3. How many distribution agreements has Kane Biotech established?
Kane Biotech has established four distribution agreements for revyve™ to date, partnering with various organizations across different regions.
4. What certifications has Kane Biotech obtained?
Kane Biotech has achieved ISO 13485:2016 certification, which is vital for marketing its products in various regions, including Canada.
5. How does Kane Biotech ensure innovation in its products?
Kane Biotech emphasizes rigorous research and development, maintaining a portfolio of numerous patents and advanced technologies aimed at preventing microbial biofilms.